Global Whooping Cough Treatment Market Highlights over 2022 – 2031
The global whooping cough treatment market is estimated to grow at a notable CAGR over the forecast period, i.e., 2022 – 2031. Whooping cough, also known as, pertussis, is a severe respiratory infection, common among children. The growth of the market can be attributed to the growing prevalence of whooping cough globally. According to the data by the World Health Organization (WHO), 151 074 cases of whooping cough were reported globally in 2018. The symptoms of whooping cough range from mild fever, runny nose and cough, to difficulty in breathing, whooping, and pneumonia. As the condition tends to be more severe for children, the rising pediatric population is estimated to boost the market growth. A report by the World Bank stated that the global population of children between 0 to 14 years reached 1.977 billion in 2020, up from 1.869 billion in 2010. Along with this, the growing health awareness among people, coupled with the adoption of advance treatment method, are anticipated to boost the market growth. Furthermore, high incidences of other lung and throat infections, including pharyngitis, and pneumonia, and rising pollution levels are also crucial factors supporting the growth of the market.
The market is segmented by patient type into pediatric, adolescents, adults, and others, out of which, the pediatric segment is anticipated to hold a substantial share in the global whooping cough treatment market over the forecast period on account of high incidences and higher severity of whooping cough amongst children. Mostly in case of children, whooping cough results in pneumonia, which is a major cause of children mortality. As per a WHO report, pneumonia accounts for 14% of all deaths of children under 5 years old every year. Moreover, pneumonia caused 740,180 deaths amongst children, in 2019.CLICK TO DOWNLOAD SAMPLE REPORT
Major Macro-Economic Indicators Impacting the Market Growth
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
Global Whooping Cough Treatment Market Regional Synopsis
On the basis of geographical analysis, the global whooping cough treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Asia Pacific region is estimated to witness noteworthy growth over the forecast period on the back of increasing pediatric population, along with growing availability of healthcare facilities in the developing regions. Moreover, the high prevalence of whooping cough in countries, such as, India, China, Japan, Philippines, Vietnam, and others, is further estimated to boost the market growth. According to the data by WHO, 12,566 cases of pertussis were reported in India, while 2,947 cases were reported in Japan, in 2020. The market in the North America region is anticipated to gain the largest market share throughout the forecast period owing to the advanced healthcare technologies present in the region, along with the presence of major pharmaceutical companies.
The global whooping cough treatment market is further classified on the basis of region as follows:
- North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
- Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
- Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
Market Segmentation
Our in-depth analysis of the global whooping cough treatment market includes the following segments:
By Patient Type
- Pediatric
- Adolescents
- Adults
- Others
By Drug Type
- Antibiotics
- Cough syrups
- Allergy Suppressants
- Others
By End-User
- Hospitals
- Pediatric Clinics
- Online Pharmacy
- Others
Growth Drivers
- Growing Prevalence of Whooping Cough
- High Incidences of Other Lung and Throat Infections, such as, Pharyngitis
- Increasing Global Pediatric Population
Challenges
- Lack of Enough Medical Practitioners in Underdeveloped Regions
- Low Adoption of Vaccines for Infants in Remote Areas
Top Featured Companies Dominating the Market
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis AG
- Pfizer Inc.
- Sanofi-aventis Groupe
- Abbott Laboratories
- Merck & Co., Inc.
- Boehringer Ingelheim International GmbH
- Daiichi Sankyo Company, Limited
- Siemens Healthcare GmbH
- Baxter International, Inc.
